Tumor cell recognition is likely based on a combination of NK cell activation by activating receptor (NKG2D, DNAM-1, NKp30, NKp44), a low expression of MHC class I on tumor cells, and mismatched KIR ligands for the graft vs. hematological malignancy effects (14–17). This evidence concerns the gene NCR2 and neoplasm.